Cost-Effectiveness of First-Line Atezolizumab versus Chemotherapy in Non-Small-Cell Lung Cancer Patients Ineligible for Platinum-Containing Regimens

Lan-Fang Li,1 Ran Qi,1 Tian-Tian Wei,1 Lei Feng,1 Xin Zhang,1 Qiao Liu2 1Department of Clinical Pharmacy, Affiliated Hospital of Jining Medical University, Jining Medical University, Jining, Shandong, 272029, People’s Republic of China; 2Department of Pharmacy, The Second Xiangya Hospital of Central...

وصف كامل

التفاصيل البيبلوغرافية
الحاوية / القاعدة:Risk Management and Healthcare Policy
المؤلفون الرئيسيون: Li LF, Qi R, Wei TT, Feng L, Zhang X, Liu Q
التنسيق: مقال
اللغة:الإنجليزية
منشور في: Dove Medical Press 2024-04-01
الموضوعات:
atezolizumab
cost-effectiveness
nsclc
ipsos. 
الوصول للمادة أونلاين:https://www.dovepress.com/cost-effectiveness-of-first-line-atezolizumab-versus-chemotherapy-in-n-peer-reviewed-fulltext-article-RMHP

الانترنت

https://www.dovepress.com/cost-effectiveness-of-first-line-atezolizumab-versus-chemotherapy-in-n-peer-reviewed-fulltext-article-RMHP

مواد مشابهة